Flo Health secures over £156m in Series C funding from General Atlantic to expand women's health platform.
General Atlantic has led a Series C investment in Flo Health that values the company at over $1bn.
Flo Health operates a widely downloaded digital health application focused on women, providing cycle tracking, symptom monitoring, and expert insights from menarche to menopause.
Flo Health has secured over £156m in a Series C funding round led by General Atlantic. The minority investment values the business at more than $1bn, marking the first time a purely digital consumer women's health application has reached unicorn status. The capital will support expansion into new segments such as perimenopause, alongside research and development initiatives across European and North American offices.
From the founder
"Reaching unicorn status is a significant milestone for Flo and the entire femtech industry,"
Dmitry Gurski
Co-founder and CEO at Flo Health
Investor perspective
"We have been lucky enough to watch the Flo team over the past five years build a beloved, mission-critical app for women globally, and now we have the fortunate opportunity to partner with Dmitry and his team. We are excited about their big vision and the innovation ahead for the broader women’s health and wellness ecosystem. We believe Flo is a category leader and look forward to leveraging our deep expertise across disruptive consumer technology and subscription platforms to support the company’s continued growth."
Jessie Cai
Principal, General Atlantic
Use of funds
- 01Fund research and development
- 02Expand into international markets
Investors
Categories
About the company
Flo Health
Flo Health operates the leading global consumer application dedicated to women's health and wellness.